domain

Pioglitazone (U 72107) is an insulin sensitizing agent and thiazolidinedione indicated for the treatment of type 2 diabetes, and has been linked to rare instances of acute liver injury.

Stafia-1 is a potent STAT5a inhibitor (IC50=22.2 μM), displaying high selectivity over STAT5b and other STAT family members.

SEB Domain (152-161) TFA represents amino acid positions 152-161 within the structural domain of staphylococcal enterotoxin B, produced by Staphylococcus aureus. This segment is highly conserved and inhibits the transcytosis of multiple staphylococcal enterotoxins, including SEA, SEE, and TSST-1.

Novel cyclic peptide that disrupts interaction between GluR6 and PSD-95

SEB Domain 144-153 acetate(210229-94-0 free base) is amino acid residues 163-172 of the staphylococcal enterotoxin B domain. SEB Domain 144-153 acetate(210229-94-0 free base) has been shown to inhibit the transcytosis of several staphylococcal enterotoxins, SEA, SEE, and TSST-1.

Tau Peptide (275-305), also known as the R2 domain fragment, represents the second repeat unit of the microtubule-binding domain of the Alzheimer's tau peptide. Tau Peptide (275-305) is considered crucial in determining the biochemical characteristics of the complete tau protein.

SEB Domain 144-153 TFA is Staphylococcal Enterotoxin B domain amino acid residue 144-153. It inhibits transcytosis of multiple staphylococcal enterotoxins, SEE, SEA, and TSST-1.

PDZ1 Domain Inhibitor Peptide TFA, a cyclic peptide featuring a β-Ala lactam side chain linker, specifically targets the PDZ1 domains of postsynaptic density protein 95 (PSD-95). It effectively disrupts the GluR6 PSD-95 interaction, competing against the C terminus of GluR6 for the PDZ1 domain with high efficiency [1].

SEB Domain (144-153) peptide is Staphylococcal Enterotoxin B domain amino acid residue 163-172. SEB Domain (144-153) has been shown to inhibit transcytosis of multiple staphylococcal enterotoxins, SEA, SEE, and TSST-1.

The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the SARS-CoV-2 RBD. [1]

Grb2 SH2 Domain Inhibitor 1 TFA is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where Φ represents L-naphthylalanine, R signifies D-arginine, and P stands for D-proline. It primarily functions as a cyclic peptide inhibitor.

Grb2 SH2 Domain Inhibitor 1 is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where Φ represents L-naphthylalanine, R denotes D-arginine, and P indicates D-proline. This compound primarily functions as a cyclic peptide inhibitor.

Bromodomain Inhibitor-12 Edisylate (example 303) serves as a bromodomain inhibitor applicable to autoimmune and inflammatory disease research [1].

BET bromodomain inhibitor is a potent BET inhibitor.

BET bromodomain inhibitor 4 (example 7) acts as an inhibitor of the BET bromodomain domain [1].

BET Bromodomain Inhibitor 3 is a BET bromodomain inhibitor with an inhibitory Ki value of >40 µM against BrdT. It is utilized in research related to contraception, cancer, and heart disease [1].

Bromodomain Inhibitor-12 (example 303) is a research compound utilized in the study of autoimmune and inflammatory diseases [1].

Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.

CBP EP300 bromodomain receptor-IN-1 (Compound 10) is an inhibitor targeting the bromodomain receptors of CBP EP300, demonstrating nanomolar-level binding affinity with proteins possessing bromodomains.

Bromodomain inhibitor-8 is an inhibitor of BET bromodomain used to treat autoimmune and inflammatory diseases.

Bromodomain inhibitor-9 is an inhibitor of Bromodomains that selectively inhibits the activity of BRD4-1 with a Kd value of 12 nM. Bromodomain inhibitor-9 can be used in studies of diseases related to systemic or lipid metabolism, tissue inflammation, fibrosis, or chronic autoimmune diseases.

Calpastatin subdomain B is a bioactive peptide that inhibits calpain activity.

Bromodomain inhibitor-10 (compound 128) is a highly potent bromodomain activity inhibitor, exhibiting strong binding affinity with Kd values of 15.0 nM and 2500 nM for BRD4-1 and BRD4-2, respectively. It also effectively inhibits the production of IL12p40 [1].

BD-IN-1, a pan bromodomain (BD) inhibitor, exhibits K_D values of 250 nM for BRD4(1), 420 nM for CBP, 130 nM for BRPF1B, 430 nM for BRD7, 67 nM for BRD9, 240 nM for BRDT(1), and 970 nM for CECR2, respectively. This compound demonstrates antiproliferative activity [1].